COSMO PHARMACEUTICALS NV financial statements, including revenue, expenses, and profit
The total revenue of COPN for the last semiannual is 131.06 M EUR, and it's 3.66% lower compared to the previous semiannual. The net income of H2 24 is 57.35 M EUR.